Truist Financial Raises Merck & Co., Inc. (NYSE:MRK) Price Target to $139.00

Merck & Co., Inc. (NYSE:MRKFree Report) had its price target lifted by Truist Financial from $122.00 to $139.00 in a research report report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also issued research reports about the company. UBS Group increased their price target on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a buy rating in a report on Friday. Barclays increased their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an overweight rating in a report on Friday. TD Cowen upgraded Merck & Co., Inc. from a market perform rating to an outperform rating and increased their price target for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. TheStreet upgraded Merck & Co., Inc. from a c+ rating to a b rating in a report on Monday, November 27th. Finally, StockNews.com initiated coverage on Merck & Co., Inc. in a research note on Thursday, October 5th. They issued a buy rating for the company. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. has an average rating of Moderate Buy and an average price target of $129.68.

Read Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 0.2 %

Shares of Merck & Co., Inc. stock opened at $126.18 on Friday. Merck & Co., Inc. has a one year low of $99.14 and a one year high of $127.80. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.38 and a quick ratio of 1.12. The stock’s 50-day moving average is $112.60 and its 200 day moving average is $107.98. The firm has a market cap of $319.74 billion, a price-to-earnings ratio of 901.29, a PEG ratio of 1.66 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.07% and a net margin of 0.61%. The company had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts anticipate that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 2,200.00%.

Insiders Place Their Bets

In other news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Jacobus Oosthuizen sold 2,081 shares of Merck & Co., Inc. stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $102.38, for a total value of $213,052.78. Following the sale, the insider now directly owns 18,191 shares of the company’s stock, valued at approximately $1,862,394.58. The disclosure for this sale can be found here. Insiders sold 96,598 shares of company stock valued at $11,236,178 over the last ninety days. 0.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently modified their holdings of MRK. Marquette Asset Management LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $26,000. Your Advocates Ltd. LLP bought a new position in Merck & Co., Inc. during the 2nd quarter valued at approximately $28,000. Rakuten Securities Inc. bought a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $30,000. RIA Advisory Group LLC bought a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $30,000. Finally, Ruedi Wealth Management Inc. raised its position in Merck & Co., Inc. by 180.2% during the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. 74.59% of the stock is currently owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

(Get Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.